The European Commission is examining commitments put forward by Vifor to resolve competition issues related to the alleged disparagement of Pharmacosmos' Monofer, a rival intravenous iron treatment.

Vifor, holding a dominant position in various national markets for intravenous iron medicines, is accused of impeding competition by disseminating misleading information about Monofer's safety to boost its own product, Ferinject.

The proposed commitments entail a corrective communication campaign, limitations on promotional messages regarding Monofer's safety, and enforcement measures for a decade.

Competition law advisors should closely follow the feedback process and its implications on Vifor's market conduct, underscoring the significance of adhering to fair competition standards in the pharmaceutical sector and the potential repercussions for firms breaching competition regulations.